MEETING ON MELBLEZTM KIT


Queensbury,NY-May 2,2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today
announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs
Advisory Committee (ODAC) voted 16 to 0 with no abstentions that benefits of
treatment with Delcath's Melblez^TM Kit (Melblez (melphalan) for Injection for
use with the Delcath Hepatic Delivery System) for the treatment of patients
with unresectable ocular melanoma metastatic to the liver do not outweigh the
risks associated with the procedure.

The FDA is not bound by the recommendation of its advisory committee, but will
consider the committee's guidance as it evaluates the Melblez Kit New Drug
Application (NDA). The Prescription Drug User Fee Act (PDUFA) goal date for
completion of the FDA's review and decision regarding approval of the Melblez
Kit NDA is September 13, 2013.

"As we conveyed during the presentation to the ODAC, we believe our clinical
trial data support Melblez Kit as an effective treatment option offering
clinical benefits to patients with unresectable metastatic ocular melanoma in
the liver" said Eamonn P. Hobbs, President and CEO of Delcath Systems. "While
we were disappointed in today's outcome, we will continue to work closely with
the FDA throughout its ongoing evaluation of Melblez Kit. We remain committed
to providing access to this promising new treatment for patients who have few
choices with regard to treatments."

About Oncologic Drugs Advisory Committee Meetings

 The FDA's Oncologic Drugs Advisory Committee (ODAC) consists of a panel of
independent experts who advise the FDA on the safety and efficacy of proposed
new cancer therapies. The panel addresses specific questions raised by the FDA
as the agency considers regulatory decisions. The FDA is not bound by the
committee's recommendation, but the agency takes its advice into consideration
when reviewing new drug applications.


Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic exposure of those agents. The Company's
initial focus is on the treatment of primary and metastatic liver cancers. In
2010, Delcath announced that its randomized Phase 3 clinical trial for
patients with metastatic melanoma in the liver had successfully achieved the
study's primary endpoint of extended hepatic progression-free survival. The
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United States, our proprietary product to deliver and filter
melphalan hydrochloride is marketed under the trade name Delcath Hepatic
CHEMOSAT^® Delivery System (CHEMOSAT Delivery System for Melphalan.) The
Company obtained authorization to affix a CE Mark for the Generation Two
CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the
CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in Europe. In October 2012, the Company satisfied all of the
requirements to affix the CE Mark to the Hepatic CHEMOSAT Delivery System
device for intra-hepatic arterial delivery and extracorporeal filtration of
doxorubicin hydrochloride injection (CHEMOSAT Delivery System for
Doxorubicin). The Company has not yet received FDA approval for commercial
sale of its system in the United States. The Company's NDA has been accepted
for filing and substantive review by the FDA. For more information, please
visit the Company's website at 

Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the impact of the negative advisory
vote by the ODAC panel on the FDA's decision regarding the Company's new drug
application (NDA), timing of completion of the FDA's review of our NDA, the
extent to which the FDA may request additional information or data and our
ability to provide the same in a timely manner, additional extensions to the
PDUFA date by the FDA, , acceptability of the Phase 1, 2 and 3 clinical trial
data by the FDA, FDA approval of the Company's NDA for the treatment of ocular
metastatic melanoma to the liver, adoption, use and resulting sales, if any,
in the United States, adoption, use and resulting sales, if any, for the
CHEMOSAT system to deliver and filter melphalan in the EEA, our ability to
successfully commercialize the chemosaturation system and the potential of the
chemosaturation system as a treatment for patients with primary and metastatic
disease in the liver, market acceptance of the Gen Two CHEMOSAT system and
patient outcomes using the same, approval of the current or future
chemosaturation system for delivery and filtration of melphalan, doxorubicin
or other chemotherapeutic agents for various indications in the US and/or in
foreign markets, actions by the FDA or other foreign regulatory agencies, our
ability to successfully enter into strategic partnership and distribution
arrangements in foreign markets including Australia and key Asian markets and
timing an revenue, if any, of the same, the approval of the Hepatic CHEMOSAT
Delivery System device to deliver and filter doxorubicin in key Asian markets
and patient outcomes using the same, our ability to obtain reimbursement for
the CHEMOSAT system, uncertainties relating to the timing and results of
research and development projects, uncertainties relating to the timing and
results of future clinical trials, and uncertainties regarding our ability to
obtain financial and other resources for any research, development and
commercialization activities. These factors, and others, are discussed from
time to time in our filings with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to reflect events
or circumstances after the date they are made.

Investor Contact:           Media Contact:
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                   EVC Group
646-445-4801/951-316-0577   646-201-5431



This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.